Table 4.

Ongoing clinical trials combining tumor-targeted therapies with PD-1/PD-L1 blockade.

Mechanism (n)	Subtype (n)	Reference
ADCC mAb (21)*	CD20	NCT02729896, NCT02846623, NCT02220842, NCT02446457, NCT02631577, NCT02535286, NCT02951156, NCT03063762, NCT03063762, NCT03121677
	CD30/CD38/CD79	NCT01716806, NCT02758717, NCT02927769, NCT02581631, NCT02431208, NCT03000452, NCT02807454, NCT02729896, NCT03057795, NCT03098550
	Others	NCT03026166, NCT03126630
Miscellaneous	Hormonal (12)	NCT02395627, NCT02990845, NCT02971761, NCT02971748, NCT02778685, NCT03007732, NCT02648477, NCT02861573, NCT02997995, NCT02985957, NCT03043664, NCT03016312
	PI3 K (5)	NCT02332980, NCT02535286, NCT02646748, NCT02637531, NCT03131908
	B-Raf/MEK (22)	NCT02818023, NCT02027961, NCT02130466, NCT02625337, NCT02902042, NCT02908672, NCT02967692, NCT01656642, NCT02902029, NCT02910700, NCT02858921, NCT01988896, NCT02586987, NCT02788279, NCT03004105, NCT02876224, NCT02607813, NCT02872259, NCT02900664, NCT02876224, NCT03108131, NCT03106415
	Invasion/Metastasis (10)	NCT02346955, NCT02717156, NCT02575404, NCT02914405, NCT02247349, NCT02563548, NCT02864381, NCT02758587, NCT02943317, NCT02546531
	Others (15)	NCT02036502, NCT02606305, NCT02771626, NCT02293980, NCT02846792, NCT02812667, NCT02512172, NCT02341625, NCT02617277, NCT03004183, NCT02831933, NCT02972034, NCT02646748, NCT03095781, NCT03050060
Tyrosine kinase inhibitors (includes small molecule inhibitors and receptor-targeted mAbs but excludes VEGF-specific TKIs)	ALK (7)	NCT02584634, NCT02393625, NCT02511184, NCT02898116, NCT02013219, NCT01998126, NCT02574078
	EGFR (19)	NCT02013219, NCT01998126, NCT02713373, NCT02088112, NCT02364609, NCT02947386, NCT02143466, NCT02454933, NCT02630186, NCT02924233, NCT02323126, NCT02124850, NCT02318901, NCT02574078, NCT01454102, NCT02819596, NCT02900664, NCT03051906, NCT03082534
	BTK (17)	NCT02420912, NCT02329847, NCT02401048, NCT02940301, NCT02362035, NCT02795182, NCT02950220, NCT02454179, NCT02403271, NCT02448303, NCT02950038, NCT02537444, NCT02362048, NCT02899078, NCT02351739, NCT02332980, NCT03021460
	c-Met (5)	NCT02323126, NCT02099058, NCT02795429, NCT02791334, NCT02954991
	HER2 (11)	NCT02924883, NCT02129556, NCT02649686, NCT02605915, NCT02689284, NCT02318901, NCT02954536, NCT02901301, NCT03125928, NCT03032107, NCT03149120
	BCR/ABL (4)	NCT02819804, NCT02011945, NCT02812693, NCT02750514
	Multi-kinase inhibitors (16)	NCT02942329, NCT02834247, NCT02988440, NCT03006926, NCT02400385, NCT02014636, NCT02133742, NCT02493751, NCT02684006, NCT02811861, NCT02853331, NCT02636725, NCT02872259, NCT03086174, NCT03081494, NCT03035630
	Others (6)	NCT03126591, NCT03049618, NCT03123055, NCT02393248, NCT02925533, NCT02546661
Thalidomide derivatives (22)	Pomalidomide	NCT02289222, NCT02576977, NCT02616640, NCT02726581, NCT02807454, NCT03023527
	Lenalidomide	NCT01953692, NCT02875067, NCT02077959, NCT02903381, NCT02906332, NCT02579863, NCT02685826, NCT02880228, NCT02963610, NCT02431208, NCT02886065, NCT02036502, NCT02631577, NCT02733042, NCT03011814, NCT03015896
Intranuclear-predominant targets (32)	CDK	NCT02684617, NCT01676753, NCT02079636, NCT02933944, NCT02791334, NCT02778685, NCT03041311
	PARP	NCT02657889, NCT02660034, NCT02734004, NCT02849496, NCT02484404, NCT02944396, NCT02546661, NCT02861573, NCT03101280, NCT03061188
	Miscellaneous	NCT02467361, NCT02483247, NCT02851004, NCT02264678, NCT02991196, NCT02983006, NCT02518958, NCT02690948, NCT02722954, NCT02419495, NCT02890069, NCT02587962, NCT03111992, NCT03012230, NCT03113188
VEGF (50)	Bevacizumab	NCT02876224, NCT02802098, NCT02921269, NCT02982694, NCT02659384, NCT02337491, NCT02873962, NCT02681549, NCT01984242, NCT02420821, NCT02348008, NCT02724878, NCT02715531, NCT01633970, NCT02291289, NCT02873195, NCT02997228, NCT02366143, NCT02891824, NCT02839707, NCT02210117, NCT02853318, NCT02410512, NCT02876224, NCT02313272, NCT02336165, NCT02574078, NCT01454102, NCT02754856, NCT03117049, NCT03050814, NCT03136406, NCT03024437, NCT03024437, NCT03074513, NCT03038100, NCT03133390
	Others	NCT02443324, NCT01688206, NCT02501096, NCT02973997, NCT02856425, NCT02791334, NCT03006887, NCT02484404, NCT02999295, NCT02572687, NCT03136627, NCT03092895, NCT03083041

^*Some trials were listed twice because they are assessing more than 1 targeted therapy. ADCC = antibody-dependent cellular cytotoxicity, ALK = anaplastic lymphoma kinase, BTK = Bruton's tyrosine kinase, CDK = cyclin dependent kinase, EGFR = epidermal growth factor receptor, HER2 = human epidermal growth factor receptor 2, mAb = monoclonal antibody, PARP = poly (ADP-ribose) polymerase, PI3 K = phosphoinositide 3-kinase, TKI = tyrosine kinase inhibitor, VEGF = vascular endothelial growth factor.